NCT03971409 - Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Stage III Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerInvasive Breast CarcinomaRecurrent Breast CarcinomaTriple-Negative Breast CarcinomaUnresectable Breast Carcinoma

Interventions

BIOLOGICAL

Anti-OX40 Antibody PF-04518600

Given IV

DRUG

Avelumab

Given IV

DRUG

Binimetinib

Given PO

BIOLOGICAL

Utomilumab

Given IV

DRUG

Liposomal Doxorubicin

Given IV

DRUG

Sacituzumab Govitecan

Given IV

Trial Locations (12)

19104

NOT_YET_RECRUITING

Abramson Cancer Center, University of Pennsylvania, Philadelphia

20057

RECRUITING

Georgetown University, Washington D.C.

21218

RECRUITING

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore

27599

RECRUITING

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

27710

RECRUITING

Duke Cancer Institute, Durham

35294

RECRUITING

O'Neal Comprehensive Cancer Center, Birmingham

37232

RECRUITING

Vanderbilt University Ingram Cancer Center, Nashville

55905

RECRUITING

Mayo Clinic, Rochester

60805

RECRUITING

University of Chicago Medicine Comprehensive Cancer Center, Evergreen Park

77030

ACTIVE_NOT_RECRUITING

Baylor College of Medicine, Houston

94143

RECRUITING

University of California, San Francisco, San Francisco

02215

RECRUITING

Dana-Farber Cancer Institute, Boston